Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress 2023
Portfolio Pulse from Benzinga Newsdesk
Altimmune announces Dr. Stephen A. Harrison will present the results of its 24-week clinical trial of pemvidutide in the treatment of NAFLD at the EASL International Liver Congress 2023. Pemvidutide is a novel peptide-based GLP-1/glucagon dual receptor agonist in development for obesity and NASH treatment.
June 15, 2023 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altimmune's presentation of pemvidutide clinical trial results at EASL International Liver Congress 2023 may positively impact its stock price.
The presentation of positive clinical trial results for pemvidutide in treating NAFLD at a prestigious international conference may increase investor confidence in Altimmune's product pipeline and potentially lead to an increase in its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100